Ernexa Therapeutics Inc. (ERNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ernexa Therapeutics Inc., a Delaware corporation, on March 20, 2026, regarding an event that occurred on March 18, 2026. The Company is headquartered in Cambridge, MA, and its common stock (ERNA) and warrants (ERNAW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On March 18, 2026, the Company received a written notice from Nasdaq indicating that its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Consequently, the Company is not eligible for the standard 180-calendar day compliance period because it effected a reverse stock split within the prior one-year period, as per Nasdaq Listing Rule 5810(c)(3)(A)(iv).
Outlook, Management Commentary, and Risks
- Management Action: The Company intends to timely request a hearing before the Nasdaq Hearing Panel. This request will automatically stay any suspension or delisting action pending the hearing.
- Compliance Plan: The Company plans to present a strategy to regain compliance with the Minimum Bid Price Requirement to the Panel. The Panel has the authority to grant an extension of up to 180 days from the date of the Notice.
- Risks and Uncertainties: There are no assurances that the Panel will grant a favorable decision or that the Company's securities will remain listed on The Nasdaq Capital Market. The filing includes standard forward-looking statement disclaimers regarding these plans.
Key Facts for Investor Verification
- Verify the current trading price of ERNA to assess the severity of the bid price deficiency.
- Confirm the date of the Company's most recent reverse stock split to understand the ineligibility for the standard compliance period.
- Monitor the status of the hearing request with the Nasdaq Hearing Panel and any subsequent rulings on extensions.
- Review the Company's specific plan to regain compliance, which may involve further corporate actions such as another reverse stock split (subject to Nasdaq rules) or capital raising.